Loading…
IOL Chemicals and Pharmaceuticals (IOLCP)₹202.95+10.13%Pharmaceuticals
In the Sep 2026 quarter (consolidated), IOL Chemicals and Pharmaceuticals reported sales of ₹793 Cr, up 40.1% from Sep 2025, and net profit of ₹64.79 Cr, up 116.5% year on year. For the year to Mar 2026, sales were ₹2,312 Cr and net profit ₹138 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 519 | 503 | 501 | 525 | 521 | 527 | 551 | 566 | 579 | 617 | 754 | 793 |
| Expenses | 477 | 455 | 452 | 485 | 476 | 465 | 491 | 511 | 524 | 528 | 654 | 687 |
| Operating Profit | 43.84 | 49.84 | 50.80 | 41.83 | 46.79 | 62.79 | 61.76 | 56.78 | 56.76 | 91.71 | 103 | 109 |
| OPM % | 9.0% | 10.1% | 10.0% | 8.0% | 9.0% | 12.0% | 11.0% | 10.1% | 10.0% | 15.0% | 14.0% | 14.0% |
| Other Income | 7.98 | 7.98 | 6.98 | 5.98 | 3.99 | 4.99 | 6.98 | 6.99 | −5.98 | 1.99 | 7.98 | 5.98 |
| Interest | 3.98 | 2.99 | 1.99 | 3.99 | 3.99 | 3.99 | 3.99 | 2.99 | 3.99 | 2.99 | 3.99 | 4.98 |
| Depreciation | 15.99 | 15.98 | 16.97 | 17.98 | 18.96 | 18.96 | 19.96 | 19.96 | 19.97 | 19.96 | 20.98 | 21.96 |
| Profit before tax | 31.98 | 36.99 | 40.01 | 26.02 | 28.01 | 44.98 | 46.01 | 40.03 | 28.01 | 71.06 | 86.99 | 87.07 |
| Tax % | 28.0% | 26.0% | 24.0% | 26.0% | 26.0% | 30.0% | 25.0% | 26.0% | 25.0% | 25.0% | 26.0% | 25.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −8.01 | 0.00 | 0.00 | 0.00 |
| Net Profit | 22.95 | 27.91 | 29.90 | 18.96 | 20.95 | 30.90 | 33.91 | 29.93 | 20.95 | 52.85 | 63.83 | 64.79 |
| EPS (Rs) | 0.80 | 0.93 | 1.03 | 0.64 | 0.69 | 1.08 | 1.15 | 1.01 | 0.71 | 1.80 | 2.18 | 2.21 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales | 2,178 | 2,213 | 2,127 | 2,074 | 2,312 | 2,744 |
| Expenses | 1,929 | 1,996 | 1,904 | 1,879 | 2,053 | 2,393 |
| Operating Profit | 258 | 225 | 230 | 201 | 269 | 360 |
| OPM % | 12.1% | 10.1% | 11.1% | 10.0% | 12.0% | 13.1% |
| Other Income | 16.95 | 24.95 | 29.93 | 21.94 | 8.98 | 9.97 |
| Interest | 7.96 | 15.94 | 15.95 | 14.94 | 14.94 | 15.95 |
| Depreciation | 42.92 | 45.92 | 62.93 | 71.85 | 79.86 | 82.87 |
| Profit before tax | 225 | 189 | 182 | 138 | 184 | 273 |
| Tax % | 25.0% | 26.0% | 26.0% | 27.0% | 25.0% | — |
| Exceptional items | −11.01 | 0.00 | 0.00 | 0.00 | −9.01 | −8.01 |
| Net Profit | 168 | 139 | 134 | 101 | 138 | 202 |
| EPS (Rs) | 5.72 | 4.73 | 4.57 | 3.45 | 4.68 | 6.90 |
| Dividend payout % | 13.9% | 16.9% | 22.0% | 22.9% | 20.9% | — |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 59.19 | 59.22 | 59.18 | 59.12 | 59.15 |
| Reserves | 1,333 | 1,448 | 1,551 | 1,626 | 1,737 |
| Borrowings | 44.11 | 80.24 | 33.06 | 117 | 135 |
| Other Liabilities | 529 | 437 | 602 | 580 | 656 |
| Total Liabilities | 1,964 | 2,023 | 2,244 | 2,382 | 2,587 |
| Fixed Assets | 559 | 751 | 931 | 1,168 | 1,179 |
| CWIP | 105 | 90.29 | 101 | 22.07 | 96.29 |
| Investments | 2.01 | 20.02 | 20.02 | 21.01 | 21.01 |
| Other Assets | 1,297 | 1,163 | 1,192 | 1,172 | 1,292 |
| Inventories | 410 | 326 | 425 | 361 | 371 |
| Trade receivables | 469 | 503 | 470 | 512 | 601 |
| Cash & equivalents | 140 | 22.04 | 143 | 208 | 198 |
| Total Assets | 1,964 | 2,023 | 2,244 | 2,382 | 2,587 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 92.95 | 122 | 290 | 179 | 214 |
| Cash from investing activity | −121 | −120 | −191 | −154 | −198 |
| Cash from financing activity | −2.01 | −4.01 | −92.06 | 46.02 | −29.03 |
| Net cash flow | −29.01 | −2.01 | 5.99 | 70.01 | −12.99 |
| Capex | 153 | 212 | 273 | 214 | 173 |
| Free cash flow | −58.05 | −87.17 | 17.01 | −34.05 | 43.04 |
| CFO / OP % | 59.9% | 75.0% | 143.9% | 96.9% | 92.9% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 80 | 84 | 82 | 91 | 96 |
| Inventory days | 96 | 78 | 112 | 96 | 92 |
| Days payable | 95 | 74 | 123 | 112 | 118 |
| Cash conversion cycle | 78 | 85 | 68 | 72 | 67 |
| Working capital days | 72 | 73 | 72 | 59 | 54 |
| ROCE % | — | 14.0% | 12.1% | 9.0% | 11.1% |
For the Sep 2026 quarter, IOL Chemicals and Pharmaceuticals reported sales of ₹793 Cr, up 40.1% year on year and net profit of ₹64.79 Cr, up 116.5% year on year. The operating margin was 14.0%.
IOL Chemicals and Pharmaceuticals' sales for the year to Mar 2026 were ₹2,312 Cr; over the last twelve months they were ₹2,744 Cr.
Net profit for the year to Mar 2026 was ₹138 Cr, and ₹202 Cr over the last twelve months. Earnings per share over the same trailing period were ₹6.90.
IOL Chemicals and Pharmaceuticals reported borrowings of ₹135 Cr at Mar 2026, against cash and equivalents of ₹198 Cr.
Cash from operations was ₹214 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹43.04 Cr.